VANCOUVER, Jan. 7 /CNW/ - Ondine Biopharma Corporation (the "Company" or
"Ondine", TSX: OBP; AIM: OBP) announces a reorganization to its senior
management team reflecting the Company's focus on the development of its
photodisinfection product pipeline. Dr. Cale Street has been appointed
Vice-President of Research of Ondine's wholly-owned subsidiary, Ondine
Research Laboratories, Inc. ("ORL"); located at the Company's research
facilities in Bothell, Washington. Mr. Thomas Dawson, who continues as an
officer of ORL, has been appointed Chief Operating Officer of the Company. Dr.
Nicolas Loebel, who continues as an officer of ORL and as Chief Technology
Officer of the Company, has been appointed President of the Company.
Carolyn Cross, who continues to hold the title of Chief Executive Officer
of the Company, has been appointed Chairman of Ondine's Board of Directors,
replacing Mr. Pierre Leduc who has resigned his positions of Executive
Chairman and a Director of the Company effective January 6, 2009. Ondine
wishes to thank Mr. Leduc for his contributions to the Company over the past 4
years and wishes him every success in his future endeavours.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
For further information:
For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
firstname.lastname@example.org; Adam Peeler, Investor Relations, The Equicom Group
Inc., (416) 815-0700 ext. 225, email@example.com; Canaccord Adams Ltd,
Nominated Adviser & Broker, Neil Johnson, Ryan Gaffney, +4420 7050 6500